Good Isn’t Good Enough: Moderna Continues Efforts to Improve COVID-19 Vaccine
Excerpt from the Article:
Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine.
One of the downsides of the vaccine initially was its cold-storage requirements. It is approved for storage at between 36 and 46 degrees F for up to 30 days and up to seven months at -4 F. Although that places some demands and limitations on healthcare providers, it’s a bit more manageable than the Pfizer-BioNTech vaccine, which requires storage at about -94 degree F, which requires specialized freezers.
However, Moderna has indicated it is working on new formulations that could extend the refrigerated shelf life. New data from the company also supports the vaccine could be refrigerated safely for three months.
Click the button below to read the entire Article:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?